Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with cervical cancer at a specific stage (FIGO 2018 stage IB3, IIA2, IIB, or IIIC1r with a tumour larger than 4 cm) who have not yet received any treatment, with staging confirmed by two qualified gynaecological specialists
• People who have at least one tumour that can be measured, based on MRI imaging results
• People whose cervical cancer has been confirmed by tissue testing to be one of three types: squamous carcinoma, adenocarcinoma (common type), or adenosquamous carcinoma
• People whose pre-surgery tissue test shows a negative PD-L1 result (a combined positive score below 1)
• People aged between 18 and 70 years old
• People who are generally able to carry out daily activities with little or no limitation (a performance score of 0 or 1 on the ECOG scale)
• People whose blood counts, liver function, and kidney function fall within acceptable ranges as determined by specific lab tests (confirm with trial site for exact values)
• People who are willing and able to follow the trial schedule and stay in contact with the trial team
• People who are willing to sign the informed consent form and agree to all trial requirements

Who may not be able to join:

• People with an active, known, or suspected autoimmune disease, or a history of one — with some exceptions for certain mild or well-controlled conditions such as vitiligo, hair loss, thyroid conditions managed with stable medication, stable type 1 diabetes, or childhood asthma that resolved completely (confirm with trial site for full list of exceptions)
• People who have previously been treated with immune checkpoint inhibitor medicines, such as anti-PD-1, anti-PD-L1, or CTLA-4 drugs, or any other treatment that works by targeting the immune system's response to cancer
• People with a known allergy or sensitivity to any ingredient in the trial medication
• People who have taken immunosuppressive drugs or high-dose steroid medicines within the 2 weeks before starting the trial (some types of steroids applied to the skin, eyes, joints, nose, or lungs are allowed)
• People who have used herbal medicines with anti-cancer effects or immune-modifying drugs within 2 weeks before starting the trial
• People with an active infection that is currently being treated with systemic (whole-body) medicines
• People who have had a serious infection in the 4 weeks before their first dose, including infections requiring hospitalisation, blood poisoning, or severe pneumonia
• People with untreated or poorly controlled hepatitis B or active hepatitis C (people with stable, treated hepatitis B or cured hepatitis C may still be considered — confirm with trial site)
• People with known active tuberculosis
• People with a weakened immune system or a positive HIV test result
• People with active inflammatory bowel disease, Crohn's disease, ulcerative colitis, or ongoing digestive problems that would severely affect the ability to take or absorb the study medicine
• People with a known lung condition affecting the lung tissue (interstitial lung disease) that causes symptoms or could interfere with identifying or treating immune-related lung problems
• People who have received a live or weakened live vaccine within 4 weeks before their first dose (standard inactivated flu vaccines are allowed)
• People who have previously had a bone marrow transplant or an organ transplant from another person
• People who have had another primary cancer diagnosis within the last 5 years
• People who have had major surgery or severe physical trauma in the 28 days before their first dose (confirm with trial site regarding specific exceptions)
• People with a history of a hole or abnormal opening in the stomach or intestines, or an abnormal passage in the female reproductive system
• People with certain serious or uncontrolled health conditions, including recent heart attack, unstable chest pain, blood clots, stroke, significant heart failure, serious bleeding, active coughing of blood, bowel obstruction, or fluid build-up in the chest or abdomen that requires repeated draining (confirm with trial site for full list)
• People who are pregnant or breastfeeding, or women who are able to become pregnant and are not willing to use contraception during the immunotherapy part of the trial
• People who are currently taking part in another interventional clinical trial (participation in observation-only studies is allowed)
• People who, in the trial doctor's judgement, may be at risk from the study medicine or are unlikely to be able to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.